Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome

被引:88
作者
Davison, TS
Yin, P
Nie, E
Kay, C
Arrowsmith, CH
机构
[1] Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada
[3] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada
基金
加拿大自然科学与工程研究理事会; 英国医学研究理事会;
关键词
p53; oligomerization; Li-Fraumeni syndrome; DNA binding;
D O I
10.1038/sj.onc.1202062
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently two germline mutations in the oligomerization domain of p53 have been identified in patients with Li-Fraumeni and Li-Fraumeni-like Syndromes. We have used biophysical and biochemical methods to characterize these two mutants in order to better understand their functional defects and the role of the p53 oligomerization domain (residues 325 -355) in oncogenesis, We find that residues 310-360 of the L344P mutant are monomeric, apparently unfolded and cannot interact with wild-type (WT) p53. The full length L344P protein is unable to bind sequence specifically to DNA and is therefore an inactive, but not a dominant negative mutant, R337C, on the other hand, can form dimers and tetramers, can hetero-oligomerize with WTp53 and can bind to a p53 consensus element. However, the thermal stability of R337C is much lower than that of M'Tp53 and at physiological temperatures more than half of this mutant is less than tetrameric, Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.
引用
收藏
页码:651 / 656
页数:6
相关论文
共 32 条
  • [1] [Anonymous], 1989, SYNTHETIC OLIGONUCLE
  • [2] CARIELLO NF, 1994, CANCER RES, V54, P4454
  • [3] Casey G, 1996, ONCOGENE, V13, P1971
  • [4] STRUCTURES OF LARGER PROTEINS IN SOLUTION - 3-DIMENSIONAL AND 4-DIMENSIONAL HETERONUCLEAR NMR-SPECTROSCOPY
    CLORE, GM
    GRONENBORN, AM
    [J]. SCIENCE, 1991, 252 (5011) : 1390 - 1399
  • [5] NMRPIPE - A MULTIDIMENSIONAL SPECTRAL PROCESSING SYSTEM BASED ON UNIX PIPES
    DELAGLIO, F
    GRZESIEK, S
    VUISTER, GW
    ZHU, G
    PFEIFER, J
    BAX, A
    [J]. JOURNAL OF BIOMOLECULAR NMR, 1995, 6 (03) : 277 - 293
  • [6] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205
  • [7] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [8] HARPER JW, 1993, CELL, V75, P805
  • [9] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53
  • [10] Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation
    Hollstein, M
    Shomer, B
    Greenblatt, M
    Soussi, T
    Hovig, E
    Montesano, R
    Harris, CC
    [J]. NUCLEIC ACIDS RESEARCH, 1996, 24 (01) : 141 - 146